Cross John Harry III 4

4 · Sonnet BioTherapeutics Holdings, Inc. · Filed Jul 2, 2020

Insider Transaction Report

Form 4
Period: 2020-07-02
Cross John Harry III
Chief Financial Officer
Transactions
  • Award

    Common Stock

    2020-07-02+78,21478,214 total
Footnotes (1)
  • [F1]On July 2, 2020, the Reporting Person was granted 78,214 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest as to 50% of the restricted stock units on April 2, 2021 and 50% of the restricted stock units on April 2, 2022.

Documents

1 file
  • 4
    ownership.xmlPrimary